StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a report issued on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company's stock.
Agile Therapeutics Trading Up 6.5 %
Shares of AGRX opened at $0.20 on Tuesday. The firm's 50-day moving average is $0.24 and its two-hundred day moving average is $0.55. Agile Therapeutics has a twelve month low of $0.18 and a twelve month high of $26.40. The firm has a market capitalization of $8.16 million, a P/E ratio of -0.01 and a beta of 1.15.
Get Agile Therapeutics alerts:Institutional Trading of Agile Therapeutics
Several large investors have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Agile Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company's stock valued at $319,000 after purchasing an additional 16,104 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Agile Therapeutics in the second quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC grew its position in shares of Agile Therapeutics by 281.3% in the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company's stock valued at $130,000 after purchasing an additional 458,300 shares during the last quarter. 19.94% of the stock is currently owned by institutional investors and hedge funds.
Agile Therapeutics Company Profile
(Get Rating)Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Further Reading
- Get a free copy of the StockNews.com research report on Agile Therapeutics (AGRX)
- Why the Cracker Barrel Selloff Looks Overcooked
- Coinbase Global Stock is a Falling Meat Cleaver
- It's Still Too Soon to Shop for Kohl's Stock
- Three Small-Cap Biotech Stocks to Consider Now
- What To Expect From The Q4 Earnings Reporting Season
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.